

mySugr Inc 111 C Street Encinitas, CA 92024

mysugr.com

Press contact

Scott K. Johnson Phone: +1 612-234-7752

Email: scott.johnson@mysugr.com

mySugr Demonstrates Clinically Significant Impact on Risk of Severe Hypoglycaemic Events

Retrospective data analysis published by ProSciento and mySugr at ADA in San Diego

SAN DIEGO, June 10, 2017 – mySugr and ProSciento, Inc., today presented data at the 77th Scientific Session of the American Diabetes Association indicating positive effects on the occurrence and severity of severe hypoglycaemic events in a high risk population, measured using Low Blood Glucose Index (LBGI), which expresses the severity and frequency of hypoglycaemic events.

The mySugr app, a registered class I medical device in the US and EU, was created to make logging of metabolic control data appealing and useful in day-to-day life, and has become a market leading digital diabetes service with more than one million registered users.

"A lot of mySugr's success is based on a true understanding of our user's needs, many in our team have diabetes themselves" said Frank Westermann, CEO & co-founder of mySugr, "We are incredibly proud to see the clinical impact we have on people's lives."

The study monitored data from 457 engaged (logging ≥5 days/week for ≥6 months users with type 1 diabetes and an elevated LBGI (being in the third quartile, or top 25%). After merely two months LBGI was reduced by 17.39% from 1.07 to 0.88, and stayed in this range. The significant reduction in LBGI indicates that using the mySugr App positively impacted the patient population. The metric has also shown a strong correlation with the future occurrence of severe hypoglycaemic events. The LBGI in the investigated population was already at an acceptable level upon inclusion, indicating a rather well controlled user base in general.

For more information, please review the poster "High Risk Population Using Mobile Logging Application Shows Significant Reduction in LBGI" by Dr. Marcus Hompesch, ProSciento's CEO, and team.

About mySugr

Founded in 2012, mySugr specializes in all-around care for people with diabetes. Its apps and services beautifully combine diabetes coaching, therapy management, unlimited test-strips, automated data tracking, and seamless integration with a growing number of medical devices to ease the daily burden of living with diabetes. The company has offices in San Diego, California and Vienna, Austria with 47 employees across both locations. The mySugr App is available in 52 countries and 13 languages.



About ProSciento

ProSciento is a full scope clinical R&D services provider exclusively focused on diabetes, NASH and obesity. The company works with clients worldwide to support their metabolic drug and device candidates as an intellectual partner to develop and implement strategies from IND/CTA and NDA/ANDA filing to post-market and investigator initiated studies, including clinical development, regulatory, licensing and partnering support. For more information, visit prosciento.com.

For more information, please visit <u>mysugr.com/press</u> and <u>mysugr.com/science</u> or get in touch with:

mySugr Inc.

Scott K. Johnson

Phone: +1 612-234-7752

Email: scott.johnson@mysugr.com

ProSciento, Inc.

Abby Devine \mid Corporate Communications

Tel: +1 858 663-6148

Email: abby.devine@prosciento.com